Home » Blog » ISPOR 2018 – “Using Real World Data to Establish an Optimal Treatment Target for Hba1c in Diabetes Type 2”

Events | Published Research

ISPOR 2018 – “Using Real World Data to Establish an Optimal Treatment Target for Hba1c in Diabetes Type 2”



Saturday, May 19



Written by TriNetX

Explore. Discover. Connect.

Presented at ISPOR 2018, this poster investigates using real world data to establish an optimal treatment target for Hba1c in diabetes type 2.

Stapff MP, Palm S, Stacey J
TriNetX Inc., Cambridge, MA, USA
ISPOR 2018

Download the poster >>

← Previous Post Next Post →

You May Also Like…

Equity in Action: Data-Driven Strategies to Advance Diversity in Clinical Trials

“Diversity in clinical trials” is undoubtedly one of the hottest topics in the healthcare industry today and with good reason. Underrepresentation in clinical...

read more

Harnessing Real-World Data to Revolutionize Chronic Lymphocytic Leukemia Research

Chronic Lymphocytic Leukemia (CLL), a type of slow-growing cancer of the blood and bone marrow, accounts for 25-30 percent of all leukemia in the Western...

read more

Detecting Pancreatic Cancer with TriNetX AI: The PDAC Risk Model Breakthrough

Powered By TriNetX MIT and BIDMC's study published by The Lancet introduces PRISM, a model for early pancreatic cancer risk, using a database of over 156...

read more